SPONSOR
Grit Biotechnology
Total Trials
3
Recruiting
3
Phases
Phase 1, Phase 2, EARLY_Phase 1
Conditions studied: Hematological Malignancy (Leukemia- Lymphoma)Autoimmune DiseasesB-cell Acute Lymphoblastic Leukemia (B-ALL)Chronic Lymphocytic Leukemia (CLL)B-cell Non-Hodgkin's Lymphoma (B-NHL)Autoimmune Hemolytic Anemia (AIHA)
Grit Biotechnology is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Hematological Malignancy (Leukemia- Lymphoma), Autoimmune Diseases, B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL).
The trial portfolio spans Phase 1, Phase 2, EARLY_Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Grit Biotechnology
How many clinical trials has Grit Biotechnology sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Grit Biotechnology, of which 3 are actively recruiting participants. These trials cover conditions including Hematological Malignancy (Leukemia- Lymphoma), Autoimmune Diseases, B-cell Acute Lymphoblastic Leukemia (B-ALL). Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Grit Biotechnology research focus on?
Grit Biotechnology clinical trials span Hematological Malignancy (Leukemia- Lymphoma), Autoimmune Diseases, B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL), B-cell Non-Hodgkin's Lymphoma (B-NHL), and additional conditions. The research pipeline includes Phase 1, Phase 2, EARLY_Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Grit Biotechnology clinical trial?
To participate in a Grit Biotechnology trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Grit Biotechnology trials with current recruitment status updated daily.
Clinical Trials by Grit Biotechnology
NCT06948981 Phase 1, Phase 2
Recruiting
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Hematological Malignancy (Leukemia- Lymphoma)
NCT07122076 EARLY_Phase 1
Recruiting
GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases
Autoimmune Diseases
NCT07205315 EARLY_Phase 1
Recruiting
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
B-cell Acute Lymphoblastic Leukemia (B-ALL)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology